Ani Pharmaceuticals (ANIP) EBT (2016 - 2025)
Historic EBT for Ani Pharmaceuticals (ANIP) over the last 15 years, with Q3 2025 value amounting to $33.8 million.
- Ani Pharmaceuticals' EBT rose 20730.84% to $33.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $50.6 million, marking a year-over-year increase of 77373.05%. This contributed to the annual value of -$22.2 million for FY2024, which is 21177.54% down from last year.
- Latest data reveals that Ani Pharmaceuticals reported EBT of $33.8 million as of Q3 2025, which was up 20730.84% from $10.5 million recorded in Q2 2025.
- Ani Pharmaceuticals' EBT's 5-year high stood at $33.8 million during Q3 2025, with a 5-year trough of -$31.5 million in Q3 2024.
- For the 5-year period, Ani Pharmaceuticals' EBT averaged around -$3.0 million, with its median value being -$2.3 million (2024).
- In the last 5 years, Ani Pharmaceuticals' EBT tumbled by 2600000.0% in 2022 and then skyrocketed by 105159.09% in 2024.
- Over the past 5 years, Ani Pharmaceuticals' EBT (Quarter) stood at -$30.9 million in 2021, then soared by 81.43% to -$5.7 million in 2022, then skyrocketed by 116.53% to $947000.0 in 2023, then crashed by 1553.22% to -$13.8 million in 2024, then soared by 345.6% to $33.8 million in 2025.
- Its last three reported values are $33.8 million in Q3 2025, $10.5 million for Q2 2025, and $20.0 million during Q1 2025.